Cannabis Inhaler Could Spread Use of Medical Marijuana

The platform is further comprised of proprietary raw Cannabis structural-modification methods, uniquely identified preloaded cartridges, and a linked clinical database that serves physicians, researchers, and healthcare entities.

Also available is the Syqe Inhaler Exo, which delivers a fixed 100 microgram dose of Cannabis for professional healthcare use. The Exo features a caregiver interface for nurses and other certified caregivers in hospital pain clinics, cancer centers, intensive care units (ICUs), and other medical institutions. Both inhalers differ from traditional vaporizers by using granules that contain standardized portions of whole Cannabis, in sizes as small as 1 mg. Device connectivity further helps monitor use and determine best dosages for different conditions.

Uniquely, 75% of the parts of the Syqe Inhaler prototype devices were printed on Stratasys (Rehovot, Israel) three dimensional (3D) printers, a convenience that sped up the manufacturing process. The Syqe Inhaler and the Syqe Inhaler Exo are products of Syqe Medical (Tel Aviv, Israel) and have been authorized for use in Israel since October 2014.

“Different materials were selected for the four main components of the device - the shell, chassis, airway, and thermal housing, which allowed them to have rigidity, clarity, biocompatibility, and heat resistance for the inhaler,” said Perry Davidson, CEO of Syqe Medical. “Since metered dose inhalation of raw botanicals is a highly unconventional undertaking, we had to develop the tooling and machines for many of our processes. More than half of our production equipment, jigs, and analytical tools were printed in house.”

Related Links:
Syqe Medical